Folic acid targeting of protein conjugates into ascites tumour cells from ovarian cancer patients.
Despite a wealth of in vitro data describing the use of folic acid for drug and DNA delivery into ovarian cancer cell lines, there have been no reports describing the targeting of such compounds to freshly isolated tumour cells. We have carried out a study to determine the usefulness of folic acid as a targeting ligand for ovarian cancer by measuring the uptake of folic acid-BSA-FITC in tumour cells isolated from the ascitic fluid of ovarian cancer patients. In 7 out of 7 patients we have found folic acid mediated uptake of the fluorescently labelled albumin, with the accumulation (average cell fluorescence) and differential uptake (ratio between receptor mediated and fluid phase uptake) varying between patients. Accumulation of folic acid-albumin FITC occurs in ascites tumour cells expressing the epithelial cell marker EMA, with a significant proportion of EMA negative cells also accumulating the conjugate. There is no correlation between cell cycle and uptake of folic acid-BSA-FITC. These results suggest that folic acid-targeting of therapeutics is a promising approach for the treatment of ovarian cancer.
Ward
C M
CM
CRC Institute for Cancer Studies, University of Birmingham, West Midlands, UK. C.M.WARD@bham.ac.uk
Acheson
N
N
Seymour
L W
LW
D001201:Ascites / Q000473:pathology*; D004247:DNA / Q000008:administration & dosage; D016503:Drug Delivery Systems; D005260:Female; D016650:Fluorescein-5-isothiocyanate / Q000378:metabolism; D005492:Folic Acid / Q000378:metabolism*; D015316:Genetic Therapy; D006801:Humans; D010051:Ovarian Neoplasms / Q000628:therapy*; D010537:Peritoneum / Q000473:pathology; D012710:Serum Albumin, Bovine / Q000008:administration & dosage* / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000378:metabolism
D012710:Serum Albumin, Bovine; D004247:DNA; D005492:Folic Acid; D016650:Fluorescein-5-isothiocyanate